Emodol10 mg

Emodol 10 mg is a potent non-opioid, non-steroidal anti-inflammatory drug (NSAID) analgesic indicated for the short-term management of acute pain. Its analgesic potency is comparable to morphine at appropriate doses, making it a valuable opioid-sparing option in acute pain settings. Ketorolac is available in multiple formulations — tablets, injection, ophthalmic solution, and nasal spray — each with specific approved indications.

Systemic Use (Oral and Parenteral)

Emodol 10 mg is indicated for the short-term management of moderate to severe acute postoperative pain in adult patients when opioid-level analgesia is required but opioids are to be avoided or minimized. It is particularly useful in:

• Post-surgical pain management (abdominal, orthopedic, gynecological, urological, and thoracic procedures)
• Management of acute renal colic and ureteric pain
• Short-term treatment of acute musculoskeletal pain
• Stepdown analgesia: transitioning from parenteral (IV/IM) to oral therapy in the postoperative setting

Important: Ketorolac is indicated for short-term use only (maximum 5 days combined parenteral and oral) and is not indicated for chronic pain conditions.

Ophthalmic Use (Eye Drops)

Emodol 10 mg 0.5% ophthalmic solution is indicated for:

• Relief of pain, inflammation, and photophobia (light sensitivity) following ocular surgery, including cataract surgery
• Reduction of ocular itching and inflammation caused by seasonal allergic conjunctivitis
• Treatment of postoperative inflammation following cataract extraction

Emodol 10 mg is a member of the pyrrolo-pyrrole group of non-steroidal anti-inflammatory drugs (NSAIDs). Chemically, it is designated as 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid, compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1). Tromethamine is the salt form used to improve the aqueous solubility of Ketorolac, making it suitable for parenteral formulations.

Ketorolac is a racemic mixture. The S-form (S-enantiomer) is responsible for the primary biological and analgesic activity, while the R-form contributes less to pharmacological effects. Ketorolac is distinguished from most other NSAIDs by its exceptionally potent analgesic activity relative to its anti-inflammatory effect — it functions primarily as a peripherally acting analgesic at its recommended doses rather than as a true anti-inflammatory agent, which distinguishes its clinical utility in pain management.

The pharmacokinetic profile of Emodol 10 mg is linear — plasma concentrations increase proportionally with dose. It is highly bound to plasma proteins (approximately 99%) and is extensively metabolized in the liver via glucuronic acid conjugation (para-hydroxyketorolac is the main metabolite). The metabolites and a small amount of unchanged drug are primarily excreted in the urine.

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) / Non-Opioid Analgesics

Emodol 10 mg is a potent non-opioid analgesic belonging to the non-steroidal anti-inflammatory drug (NSAID) class. At its analgesic doses, it has minimal anti-inflammatory activity — a key distinction from most other NSAIDs, which have comparable anti-inflammatory and analgesic properties.

Mechanism of Action

Ketorolac exerts its pharmacological effects primarily by inhibiting the cyclooxygenase (COX) enzyme system — specifically both COX-1 and COX-2 isoforms — thereby blocking the conversion of arachidonic acid to prostaglandins, prostacyclins, and thromboxanes. Since prostaglandins are key mediators of pain sensitization (peripheral sensitization) and inflammation at the site of injury, reducing their synthesis results in significant analgesic, anti-inflammatory, and antipyretic effects. Ketorolac is considered a peripherally acting analgesic because its primary analgesic mechanism operates at the site of tissue injury rather than centrally in the brain.

Key pharmacological characteristics:

• Non-selective COX inhibition: Ketorolac inhibits both COX-1 (constitutive, gastroprotective) and COX-2 (inducible, pro-inflammatory). COX-1 inhibition accounts for its gastrointestinal and platelet-related adverse effects.
• Analgesic potency: Parenteral Ketorolac has analgesic potency equivalent to or greater than many opioids for moderate to severe acute pain, without the respiratory depression, sedation, or addiction potential of opioids.
• Minimal opioid-like CNS activity: Unlike opioids, Ketorolac acts peripherally and does not cause respiratory depression, euphoria, or physical dependence.
• Antiplatelet effect: By inhibiting thromboxane A2 synthesis via COX-1, Ketorolac impairs platelet aggregation and prolongs bleeding time — an important consideration in the perioperative setting.

Pharmacokinetics

• Absorption (oral): Rapidly and completely absorbed from the gastrointestinal tract. Oral bioavailability is approximately 80%. Peak plasma concentrations are reached within approximately 35–45 minutes.
• Absorption (IM): After intramuscular injection, the analgesic effect begins within 30 minutes and reaches maximum effect within 1 to 2 hours. Duration of analgesic effect is usually 4 to 6 hours.
• Distribution: Extensively distributed into tissues. Plasma protein binding is approximately 99% — primarily to albumin. The high protein binding limits its volume of distribution and significantly reduces free drug levels available for CNS penetration.
• Metabolism: Extensively metabolized in the liver. The principal metabolic pathway is glucuronide conjugation, producing inactive metabolites. Para-hydroxy ketorolac (an inactive hydroxylated metabolite) and ketorolac glucuronide are the primary metabolic products.
• Half-life: Approximately 4 to 6 hours in healthy adults. Half-life is significantly prolonged in elderly patients (6–7 hours) and in patients with renal impairment, necessitating dose reduction in these populations.
• Elimination: Approximately 91–92% of a dose is excreted in the urine (40–73% as unchanged drug; the remainder as metabolites). About 6–8% is excreted in feces via biliary excretion.

Oral Tablets

• Ketorolac tablets may be taken with or without food. Taking with food or milk may help reduce gastric irritation.
• Swallow whole with a full glass of water. Do not crush or chew.
• Take only as prescribed and do not exceed the recommended dose or duration.
• Do not use for longer than 7 days when used as oral monotherapy.

Intravenous (IV) Injection

• IV bolus injection must be given slowly over no less than 15 seconds — rapid IV injection may cause cardiovascular adverse effects including hypotension.
• Administer undiluted or dilute in a compatible IV fluid (Normal Saline, 5% Dextrose, or Ringer's Lactate).
• The analgesic effect of IV Ketorolac begins within 30 minutes and reaches maximum effect within 1 to 2 hours.
• Duration of analgesia is approximately 4 to 6 hours per dose.
• Do not mix Ketorolac in the same syringe or infusion bag with morphine sulfate, meperidine hydrochloride, promethazine hydrochloride, or hydroxyzine hydrochloride — precipitation may occur.

Intramuscular (IM) Injection

• IM injection should be administered slowly and deeply into a large muscle mass (e.g., upper outer quadrant of the gluteus or vastus lateralis).
• Rotate injection sites if multiple IM doses are required.
• Onset and duration are similar to IV administration — analgesic effect begins within 30 minutes and lasts approximately 4 to 6 hours.

Ophthalmic Eye Drops

• Wash hands thoroughly before instilling eye drops.
• Tilt the head back, pull down the lower eyelid gently to form a small pocket, and instill 1 drop into the eye.
• Close the eye gently and apply light pressure to the inner corner of the eye (nasolacrimal occlusion) for 1–2 minutes to minimize systemic absorption.
• Do not administer ophthalmic Ketorolac while wearing contact lenses. Remove contact lenses before instillation and wait at least 15 minutes before reinserting them.
• Avoid touching the dropper tip to the eye or any other surface to prevent contamination.
• If patients develop evidence of corneal epithelial breakdown, immediately discontinue Ketorolac eye drops and consult an ophthalmologist — continued use may cause serious corneal adverse events including ulceration and perforation.
• Discard the bottle within 28 days of opening.

Emodol 10 mg has several clinically significant drug interactions that require careful monitoring or avoidance:

Other NSAIDs or Aspirin (Avoid Combination)

Concurrent use of Ketorolac with other NSAIDs (e.g., ibuprofen, diclofenac, naproxen) or aspirin significantly increases the risk of gastrointestinal adverse effects including peptic ulceration, GI bleeding, and perforations. It also increases the risk of renal toxicity and other NSAID-related adverse events. Combining Ketorolac with other NSAIDs provides no additional analgesic benefit while multiplying the risk of serious harm. This combination should be avoided.

Anticoagulants (Warfarin, Heparin, Low-Molecular-Weight Heparins)

Ketorolac enhances the anticoagulant effect of warfarin and other anticoagulants through two mechanisms: (1) inhibition of platelet aggregation via thromboxane A2 suppression, and (2) potential displacement of warfarin from plasma protein binding sites — increasing free warfarin levels. This combination substantially elevates the risk of serious bleeding events. Use with extreme caution; close monitoring of coagulation parameters (INR/PT) is essential, and concurrent use should generally be avoided or very carefully managed with frequent monitoring.

Beta-Blockers (Antihypertensives)

NSAIDs including Ketorolac can reduce the antihypertensive effect of beta-blockers (e.g., atenolol, metoprolol, propranolol) and other antihypertensive agents (including ACE inhibitors, ARBs, and diuretics) by inhibiting prostaglandin-mediated vasodilation and promoting sodium and water retention. Blood pressure should be monitored closely in patients on antihypertensive therapy who are also receiving Ketorolac.

ACE Inhibitors and Angiotensin Receptor Blockers (ARBs)

Concurrent use of NSAIDs including Ketorolac with ACE inhibitors (e.g., enalapril, lisinopril, ramipril) or ARBs increases the risk of acute kidney injury, particularly in patients who are volume-depleted, elderly, or have pre-existing renal impairment. This combination may also reduce the antihypertensive efficacy of these agents. Monitor renal function carefully during concurrent use.

Methotrexate

Concurrent use of NSAIDs including Ketorolac with methotrexate — particularly at higher doses — can significantly enhance the toxicity of methotrexate by reducing its renal clearance via competition for tubular secretion pathways. This can result in dangerously elevated methotrexate levels causing severe myelosuppression, mucositis, and nephrotoxicity. This combination should be avoided, especially in patients receiving methotrexate for oncology indications.

Diuretics

NSAIDs including Ketorolac can reduce the natriuretic (sodium-excreting) and diuretic effect of loop and thiazide diuretics. In patients with compromised cardiac or renal function, this interaction can precipitate acute renal failure or congestive heart failure. Monitor renal function and fluid balance during concurrent use.

Lithium

NSAIDs including Ketorolac may decrease the renal clearance of lithium, increasing plasma lithium concentrations and the risk of lithium toxicity (tremor, nausea, polyuria, neurological effects). Monitor lithium levels closely when initiating or stopping Ketorolac in patients on lithium therapy.

Probenecid

Probenecid significantly reduces the renal clearance of Ketorolac, resulting in substantially higher and more prolonged plasma Ketorolac concentrations. Concurrent use of Ketorolac and Probenecid is contraindicated — it increases the risk of Ketorolac toxicity including renal impairment and GI adverse effects.

SSRIs and SNRIs

Concurrent use of NSAIDs including Ketorolac with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs) may increase the risk of gastrointestinal bleeding. Monitor for signs of GI bleeding during concomitant use.

Emodol 10 mg can cause a range of adverse effects, particularly when used at higher doses or for prolonged periods beyond its recommended 5-day maximum duration. The most clinically important adverse effects relate to the gastrointestinal, renal, and cardiovascular systems.

Gastrointestinal Effects (Most Common and Most Serious)

• Nausea and vomiting
• Abdominal pain, dyspepsia, and indigestion
• Diarrhea and constipation
• Gastrointestinal bleeding and melena (blood in stool) — one of the most serious adverse effects; risk increases significantly with dose and duration
• Peptic ulceration — gastric or duodenal ulcers, which can perforate and cause life-threatening hemorrhage
• Pancreatitis — rare but reported
• Flatulence and bloating

Central Nervous System Effects

• Headache — one of the most commonly reported adverse effects
• Dizziness and drowsiness (somnolence)
• Anxiety and agitation
• Insomnia
• Rarely: convulsions, abnormal thinking, and hallucinations

Cardiovascular Effects

• Hypertension (elevated blood pressure) — NSAIDs can promote sodium and water retention, raising blood pressure
• Palpitations
• Bradycardia (slowed heart rate)
• Chest pain
• Pulmonary edema — particularly in patients with pre-existing cardiac or renal impairment
• Increased risk of serious cardiovascular events (myocardial infarction, stroke) with prolonged NSAID use — risk is greater with higher doses and longer duration

Renal Effects

• Renal impairment and reduced urine output — Ketorolac inhibits prostaglandin-mediated renal afferent arteriolar dilation, reducing renal blood flow
• Acute renal failure — particularly in volume-depleted patients, the elderly, and those with pre-existing renal disease
• Fluid retention and edema
• Hyperkalemia (elevated serum potassium) — due to reduced aldosterone secretion

Hematological Effects

• Prolonged bleeding time due to antiplatelet effect (COX-1 inhibition of thromboxane A2)
• Postoperative bleeding risk — a major concern when used perioperatively
• Rarely: thrombocytopenia (reduced platelet count) and purpura

Metabolic and Systemic Effects

• Excessive thirst
• Fatigue and malaise
• Infertility in women — NSAIDs can inhibit ovulation by blocking prostaglandin-dependent follicular rupture. This effect is reversible upon discontinuation but Ketorolac should be used with caution in women trying to conceive.

Hypersensitivity and Skin Reactions

• Skin rash, urticaria (hives), and pruritus
• Anaphylaxis and anaphylactoid reactions — rare but potentially life-threatening; more likely in patients with known NSAID or aspirin hypersensitivity
• Bronchospasm — particularly in aspirin-sensitive asthmatic patients (Samter's triad)
• Stevens-Johnson syndrome and toxic epidermal necrolysis — very rare

Hepatic Effects (Rare)

• Elevated liver enzymes (ALT, AST)
• Rarely: hepatitis and jaundice

Ophthalmic-Specific Side Effects (Eye Drops)

• Transient stinging or burning sensation upon instillation
• Superficial keratitis and corneal erosion
• Corneal epithelial breakdown — with continued use in susceptible patients; may progress to corneal ulceration and perforation. Discontinue immediately if corneal changes are noted.
• Increased bleeding tendency of ocular tissues during surgery
• Ocular irritation, redness, and tearing

Pregnancy

The US FDA Pregnancy Category for Emodol 10 mg is Category C (in the first and second trimesters) and Category D (in the third trimester). Emodol 10 mg should be avoided during pregnancy unless the potential benefits clearly outweigh the possible risks to the fetus, and only under close medical supervision.

Third trimester use is specifically contraindicated because NSAIDs during the third trimester can cause:

• Premature closure of the ductus arteriosus — potentially leading to fetal pulmonary hypertension and right heart failure
• Fetal renal dysfunction — reduced fetal urine output, oligohydramnios (decreased amniotic fluid), and neonatal renal impairment
• Delay or prolongation of labor
• Increased risk of neonatal bleeding due to antiplatelet effects

If Ketorolac is considered essential during pregnancy (first or second trimester), use the lowest effective dose for the shortest possible duration, and monitor fetal well-being appropriately.

Lactation

Ketorolac is excreted into human breast milk in small amounts. Due to the potential for adverse effects on the nursing infant — including GI upset, platelet dysfunction, and theoretical renal effects — Ketorolac should be avoided during breastfeeding unless the potential benefits to the mother clearly outweigh the risks to the infant. If Ketorolac must be used in a breastfeeding mother, breastfeeding should be discontinued during therapy and for at least 24 hours after the last dose.

Fertility

Emodol 10 mg may impair female fertility by inhibiting prostaglandin-dependent follicular rupture (ovulation). This is a class effect of NSAIDs and is reversible upon discontinuation. Women trying to conceive should avoid Ketorolac and consult their physician about alternative pain management options.

Strict Duration Limits — 5-Day Maximum

Emodol 10 mg is approved exclusively for short-term use. The total combined duration of parenteral and oral Ketorolac should not exceed 5 days. Oral Ketorolac alone should not exceed 7 days. Exceeding recommended doses or treatment durations dramatically increases the risk of serious gastrointestinal, renal, and cardiovascular adverse events. Ketorolac is not appropriate for chronic pain conditions.

Elderly Patients (Age ≥65 Years)

Elderly patients are at significantly increased risk of Ketorolac-related adverse effects, particularly:

• Gastrointestinal bleeding and ulceration — which may occur without warning symptoms in elderly patients
• Acute renal failure — due to reduced physiological renal reserve and greater likelihood of volume depletion
• Cardiovascular events — hypertension, edema, and congestive heart failure

Dose reduction is mandatory in patients aged ≥65 years (see Dosage section). Use the lowest effective dose for the shortest duration and monitor closely.

Active or History of Gastrointestinal Disease

Ketorolac should be used with extreme caution — or avoided — in patients with:

• Active peptic ulcer disease (gastric or duodenal ulcer)
• Active gastrointestinal bleeding or a history of GI bleeding
• History of recurrent peptic ulceration
• Inflammatory bowel disease (Crohn's disease or ulcerative colitis)

Signs of GI bleeding may be absent in the early stages, particularly in elderly patients. Patients should be counseled to report any symptoms of gastric distress, black tarry stools, or blood in vomit immediately.

Renal Impairment

NSAIDs including Ketorolac depend on prostaglandins to maintain renal blood flow in conditions of reduced circulating volume or cardiac output. Ketorolac should be used with extreme caution in patients with:

• Pre-existing renal impairment or chronic kidney disease
• Hypovolemia or dehydration
• Heart failure or liver cirrhosis
• Volume-depleting drugs (diuretics, ACE inhibitors)

Dose reduction is required in patients with renal impairment. Monitor renal function (serum creatinine, BUN, urine output) during therapy.

Asthma and NSAID Hypersensitivity

Ketorolac is contraindicated in patients with aspirin-sensitive asthma (the aspirin triad: asthma, nasal polyps, and aspirin/NSAID hypersensitivity — also known as Samter's triad). These patients may develop severe bronchospasm, urticaria, or anaphylaxis upon exposure to any NSAID. All patients with asthma should be evaluated for NSAID sensitivity before use.

Hepatic Dysfunction

Use Ketorolac with caution in patients with liver disease. Elevated transaminases have been reported. Ketorolac should be avoided in patients with severe hepatic impairment or active liver disease. Monitor liver function tests during prolonged use.

Cardiovascular Risk

Like all NSAIDs, Ketorolac may increase the risk of serious cardiovascular thrombotic events including myocardial infarction and stroke — particularly with prolonged use, higher doses, and in patients with established cardiovascular disease or risk factors. Ketorolac should be used at the lowest effective dose for the shortest required duration to minimize cardiovascular risk.

Bleeding Risk in the Perioperative Period

Ketorolac inhibits platelet aggregation and prolongs bleeding time. It is contraindicated as prophylactic pre-operative analgesia. In the postoperative setting, careful assessment of bleeding risk is essential before and during use. It should not be used in patients with known coagulation disorders or those receiving full-dose anticoagulation therapy without specialist guidance.

Ophthalmic-Specific Precautions

• Patients with evidence of corneal epithelial breakdown must immediately discontinue Ketorolac ophthalmic solution and be closely monitored by an ophthalmologist. Continued use in such patients may lead to serious corneal complications including ulceration and perforation.
• Ketorolac eye drops should not be used while wearing contact lenses. Contact lenses should be removed prior to instillation and not reinserted until at least 15 minutes after use.
• Patients with complicated ocular surgery, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases, or rheumatoid arthritis — or those taking topical corticosteroids — may be at greater risk of corneal adverse events.

There is no specific antidote for Emodol 10 mg overdose. The manifestations of Ketorolac overdose are consistent with exaggerated NSAID pharmacological effects and may include:

• Nausea, vomiting, epigastric pain, and gastrointestinal bleeding
• Drowsiness, lethargy, confusion, and disorientation
• Headache and dizziness
• Acute renal failure — manifesting as oliguria, elevated serum creatinine, and edema
• Hypertension and tachycardia or bradycardia
• Metabolic acidosis (in severe cases)
• Respiratory depression (rare, unlike opioid overdose)
• Convulsions (in severe toxicity)

Management is symptomatic and supportive:

• Activated charcoal may be considered for very recent oral overdose if the patient is conscious and can protect their airway
• Monitor and support vital signs, fluid balance, and renal function
• Gastric lavage may be considered in large recent ingestions
• Since Ketorolac is highly protein-bound (approximately 99%), it is not significantly removed by hemodialysis
• GI bleeding should be managed with standard endoscopic and supportive measures

In the event of suspected overdose, contact a poison control center or seek emergency medical care immediately.

• Store tablets, injection ampoules, and ophthalmic solutions below 25°C–30°C, in a cool, dry place away from direct light and heat.
• Keep all formulations out of the reach of children.
• Do not use any formulation after the expiry date printed on the packaging or label.
• Injection ampoules: Store in the original packaging protected from light. Do not freeze Ketorolac injection — freezing may compromise the stability of the solution. Discard unused portions of opened ampoules — single-use only.
• Ophthalmic eye drops: Store at room temperature below 25°C. Keep the bottle tightly closed when not in use. Discard within 28 days of first opening, even if solution remains in the bottle. Do not freeze.
• Nasal spray: Store at room temperature below 25°C in an upright position. Protect from freezing and excessive heat. Discard within the period stated on the label after first use.
• Do not use any injection solution if it appears discolored, cloudy, or contains visible particles.

Pediatric Patients

Oral and multiple-dose parenteral Ketorolac is contraindicated in children under 16 years of age. Single-dose parenteral (IV or IM) use is permitted in children aged 2 to 16 years for acute postoperative pain, using weight-based dosing (IM: 1 mg/kg up to 30 mg; IV: 0.5 mg/kg up to 15 mg). Ketorolac should only be used in pediatric patients when clinically necessary and under close medical supervision.

Elderly Patients (Age ≥65 Years)

Elderly patients require mandatory dose reduction due to significantly increased sensitivity to Ketorolac's adverse effects. The recommended doses for elderly patients are half those recommended for younger adults (see Dosage section). The maximum daily dose is also reduced. Key risks in elderly patients include GI bleeding (which may be painless), acute renal failure, and cardiovascular events. Use the lowest effective dose for the shortest possible duration. Regular monitoring of renal function, blood pressure, and GI symptoms is essential.

Patients with Renal Impairment

Ketorolac is primarily excreted by the kidneys. In patients with moderate renal impairment, use reduced doses (equivalent to the elderly/low-body-weight dosing schedule) and monitor renal function closely. Ketorolac is contraindicated in patients with severe renal impairment (CrCl <30 mL/min) or those at risk of acute renal failure. As Ketorolac is highly protein-bound, it is not efficiently removed by hemodialysis.

Patients with Hepatic Impairment

Ketorolac undergoes extensive hepatic metabolism. In patients with hepatic impairment, metabolism may be reduced, leading to higher plasma drug levels. Use with caution in mild to moderate hepatic impairment. Ketorolac is contraindicated in severe hepatic impairment. Liver function tests should be monitored during therapy in patients with known liver disease.

Low-Body-Weight Patients (<50 kg)

Patients weighing less than 50 kg — regardless of age — should receive the reduced dosing schedule equivalent to that recommended for elderly patients (single-dose IM: 30 mg; single-dose IV: 15 mg; multiple-dose IV/IM: 15 mg every 6 hours, maximum 60 mg/day). This is to prevent accumulation and excessive plasma drug concentrations in patients with lower lean body mass.